in

Gene editing biotechnology company: Kiromic Biopharma (KRBP) (2006)

Kiromic Biopharma, Inc. (NASDAQ: KRBP) was founded in 2006 and is headquartered in Houston, Texas, with 11 full-time employees. It is a company that uses artificial intelligence and the company’s proprietary neural network platform for target discovery and gene editing. The focus of its treatment is immuno-oncology. The company’s proprietary target discovery engine is called “Diamond”.

Kiromic Biopharma

Kiromic Biopharma (KRBP):

Diamond is a computing platform and neural network that can identify new cancer immunological targets of T cells and B cells. Diamond is an artificial intelligence bioinformatics method that can identify novel surface tumor targets. It uses public and proprietary samples and can be extended to the tumor target space.

Diamond

Diamond is a neural network composed of predictive analysis, machine learning and artificial intelligence. These neural networks can determine the best goals even before the start of preclinical and clinical development.

Diamond’s cognitive and deep learning capabilities extract information from the company’s extensive digital library, which includes clinical research, genomics and proteomics data sets. Diamond coordinates all raw data and creates a data set that enables the company to screen cancer targets. Diamond will identify and prioritize genes that are highly specifically expressed in the target disease (biomarkers, wild-type, mutants, isoforms, new epitopes, etc.), and provide their distribution and methyl groups in the entire patient population.化 status.

Kiromic Biopharma Pipeline

Kiromic Biopharma product line

Kiromic Biopharma (KRBP) financing:

  • On October 7, 2013, in the seed round, Kiromic Biopharma received US$105,000 in funding.
  • On June 1, 2014, in the seed round, Kiromic Biopharma received an investment of US$5.2 million.
  • On June 8, 2016, in the seed round, Kiromic Biopharma received another US$6.7 million in funding.
  • On May 1, 2018, in the Series A financing, Kiromic Biopharma received an investment of USD 1.2 million.
  • On August 1, 2019, Kiromic Biopharma conducted Series B financing.

Kiromic Biopharma (KRBP) investment:

Kiromic Biopharma, Inc. (NASDAQ: KRBP) plans to list on NASDAQ on 10/16/2020 IPO, issue price $12.00-$14.00, issue 1.2 million shares, raise $15.6 million, ThinkEquity (a division of Fordham Financial Management) ) Underwriting, joint Paulson Investment Company.

The companies listed on the same day are: Praxis Precision Medicines , Kiromic Biopharma , Aligos Therapeutics , Eargo, Inc. and Tarsus Pharmaceuticals .

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Regional bank holding company: Cambridge Bancorp (CATC) (1890)

Petro-Canada: TransGlobe Energy Corporation (TGA)